{"id":5824,"date":"2026-05-22T10:44:00","date_gmt":"2026-05-22T10:44:00","guid":{"rendered":"https:\/\/www.nfp-drugs.bg\/en\/?p=5824"},"modified":"2026-07-22T11:13:59","modified_gmt":"2026-07-22T11:13:59","slug":"prevalence-of-hiv-hepatitis-b-c-and-syphilis-infection-among-people-who-inject-drugs-over-the-period-trends","status":"publish","type":"post","link":"https:\/\/www.nfp-drugs.bg\/en\/prevalence-of-hiv-hepatitis-b-c-and-syphilis-infection-among-people-who-inject-drugs-over-the-period-trends\/","title":{"rendered":"Prevalence of HIV, hepatitis B\/C and syphilis infection among people who inject drugs over the period 2013 – 2025 (data from SPHTDAA Laboratory, Sofia)"},"content":{"rendered":"\n
\n
<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
Prevalence of psychoactive substance use
Prevalence of medication use
Prevalence of drug use
Drug Prevention<\/a><\/strong><\/td>		Treatment Supply<\/a>
Treatment Demand
Health consequences<\/a>
Harm reduction<\/a><\/strong><\/td>		Drug-related crimes<\/a>
Drug market<\/a>
Drug use and prison<\/a>
Monitoring of publications<\/a>
Attitudes to legal framework changes<\/a><\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Database (1995-2025).xlsx<\/a><\/strong><\/p>\n\n\n\n

Prevalence of HIV infection among people who inject drugs (PWID) over the period 2013 – 2025<\/strong><\/p>\n\n\n\n

<\/td>2013<\/strong><\/td>2014<\/strong><\/td>2015<\/strong><\/td>2016<\/strong><\/td>2017<\/strong><\/td>2018<\/strong><\/td>2019<\/strong><\/td>2020<\/strong><\/td>2021<\/strong><\/td>2022<\/strong><\/td>2023<\/strong><\/td>2024<\/strong><\/td>2025<\/strong><\/td><\/tr>
Total number of PWID who were tested<\/strong><\/strong><\/td>822<\/strong><\/td>661<\/strong><\/td>698<\/strong><\/td>332<\/strong><\/td>319<\/strong><\/td>378<\/strong><\/td>383<\/strong><\/td>254<\/strong><\/td>305<\/strong><\/td>262<\/strong><\/td>203<\/strong><\/td>150<\/strong><\/td>180<\/strong><\/td><\/tr>
Males<\/td>607<\/td>366<\/td>550<\/td>240<\/td>234<\/td>281<\/td>272<\/td>167<\/td>220<\/td>192<\/td>145<\/td>99<\/td>133<\/td><\/tr>
Females<\/td>215<\/td>122<\/td>148<\/td>92<\/td>85<\/td>97<\/td>111<\/td>87<\/td>85<\/td>70<\/td>58<\/td>49<\/td>42<\/td><\/tr>
No data<\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td>2<\/td>5<\/td><\/tr>
Number of PWID with a positive test result<\/strong><\/td>28<\/strong><\/td>25<\/strong><\/td>30<\/strong><\/td>10<\/strong><\/td>1<\/strong>9<\/td>13<\/strong><\/td>49<\/strong><\/td>37<\/strong><\/td>15<\/strong><\/td>38<\/strong><\/td>32<\/strong><\/td>18<\/strong><\/td>33<\/strong><\/td><\/tr>
Males<\/td>21<\/td>15<\/td>24<\/td>7<\/td>17<\/td>12<\/td>40<\/td>28<\/td>14<\/td>30<\/td>29<\/td>17<\/td>28<\/td><\/tr>
Females<\/td>7<\/td>1<\/td>6<\/td>3<\/td>2<\/td>1<\/td>9<\/td>9<\/td>1<\/td>8<\/td>3<\/td>1<\/td>4<\/td><\/tr>
No data<\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td>1<\/td><\/tr>
Proportion positive (%)<\/strong><\/td>3.4%<\/strong><\/td>3.8%<\/strong><\/td>4.3%<\/strong><\/td>3.0%<\/strong><\/td>6.0%<\/strong><\/td>3.4%<\/strong><\/td>12.8%<\/strong><\/td>14.6%<\/strong><\/td>4.9%<\/strong><\/td>14.5%<\/strong><\/td>15.8%<\/strong><\/td>12.0%<\/strong><\/td>18.3%<\/strong><\/td><\/tr>
Males<\/td>3.5%<\/td>4.1%<\/td>4.4%<\/td>2.9%<\/td>7.3%<\/td>4.3%<\/td>14.7%<\/td>16.8%<\/td>6.4%<\/td>15.6%<\/td>20.0%<\/td>17.2%<\/td>21.1<\/td><\/tr>
Females<\/td>3.3%<\/td>0.8%<\/td>4.1%<\/td>3.3%<\/td>2.4%<\/td>1.0%<\/td>8.1%<\/td>10.3%<\/td>1.2%<\/td>11.4%<\/td>5.2%<\/td>2.0%<\/td>9.5<\/td><\/tr>
Age <25<\/strong><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>66<\/td>52<\/td>86<\/td>57<\/td><\/td>25<\/td>14<\/td>6<\/td>11<\/td>16<\/td>2<\/td>3<\/td>4<\/td><\/tr>
Number of PWID with a positive test result<\/td>4<\/td>1<\/td>6<\/td>1<\/td><\/td>0<\/td>0<\/td>0<\/td>0<\/td>0<\/td>0<\/td>0<\/td>0<\/td><\/tr>
Proportion positive (%)<\/td>6.1%<\/td>1.9%<\/td>7.0%<\/td>1.8%<\/td><\/td>0.0%<\/td>0.0%<\/td>0.0%<\/td>0.0%<\/td>0.0%<\/td>0.0%<\/td>0.0%<\/td>0.0%<\/td><\/tr>
Age 25-34<\/strong><\/strong><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>469<\/td>228<\/td>340<\/td>137<\/td><\/td>80<\/td>36<\/td>27<\/td>53<\/td>22<\/td>16<\/td>18<\/td>13<\/td><\/tr>
Number of PWID with a positive test result<\/td>14<\/td>11<\/td>12<\/td>3<\/td><\/td>4<\/td>13<\/td>7<\/td>3<\/td>3<\/td>3<\/td>2<\/td>0<\/td><\/tr>
Proportion positive (%)<\/td>3.0%<\/td>4.8%<\/td>3.5%<\/td>2.2<\/td><\/td>5.0%<\/td>36.1%<\/td>25.9%<\/td>5.7%<\/td>13.6%<\/td>18.75<\/td>11.1%<\/td>0.0%<\/td><\/tr>
Age > 34<\/strong><\/strong><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>287<\/td>198<\/td>272<\/td>138<\/td><\/td>273<\/td>333<\/td>221<\/td>241<\/td>224<\/td>185<\/td>129<\/td>163<\/td><\/tr>
Number of PWID with a positive test result<\/td>10<\/td>4<\/td>12<\/td>6<\/td><\/td>9<\/td>36<\/td>30<\/td>12<\/td>35<\/td>29<\/td>16<\/td>33<\/td><\/tr>
Proportion positive (%)<\/td>3.5%<\/td>2.0%<\/td>4.4%<\/td>4.3%<\/td><\/td>3.3%<\/td>10.8%<\/td>13.6%<\/td>5.0%<\/td>15.6%<\/td>15.7%<\/td>12.4%<\/td>20.2<\/td><\/tr><\/tbody><\/table>
Note: PWID are defined as people who have injected drugs at some point in their life.<\/sub><\/strong><\/figcaption><\/figure>\n\n\n\n

Prevalence of hepatitis B infection among people who inject drugs (PWID) over the period 2013 – 2025<\/strong><\/p>\n\n\n\n

<\/td>2013<\/strong><\/td>2014<\/strong><\/td>2015<\/strong><\/td>2016<\/strong><\/td>2017<\/strong><\/td>2018<\/strong><\/td>2019<\/strong><\/td>2020<\/strong><\/td>2021<\/strong><\/td>2022<\/strong><\/td>2023<\/strong><\/td>2024<\/strong><\/td>2025<\/strong><\/td><\/tr>
Total number of PWID who were tested<\/strong><\/strong><\/td>756<\/strong><\/td>634<\/strong><\/td>698<\/strong><\/td>332<\/strong><\/td>98<\/strong><\/td>359<\/strong><\/td>374<\/strong><\/td>118<\/strong><\/td>259<\/strong><\/td>118<\/strong><\/td>203<\/strong><\/td>150<\/strong><\/td>180<\/strong><\/td><\/tr>
Males<\/td>560<\/td>350<\/td>550<\/td>240<\/td>71<\/td>257<\/td>266<\/td>82<\/td>185<\/td>94<\/td>144<\/td>99<\/td>133<\/td><\/tr>
Females<\/td>196<\/td>124<\/td>148<\/td>92<\/td>27<\/td>102<\/td>108<\/td>36<\/td>74<\/td>24<\/td>59<\/td>49<\/td>42<\/td><\/tr>
No data<\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td>2<\/td>5<\/td><\/tr>
Number of PWID with a positive test result<\/strong><\/td>34<\/strong><\/td>38<\/strong><\/td>25<\/strong><\/td>6<\/strong><\/td>5<\/strong><\/td>19<\/strong><\/td>22<\/strong><\/td>9<\/strong><\/td>15<\/strong><\/td>21<\/strong><\/td>30<\/strong><\/td>3<\/strong><\/td>12<\/strong><\/td><\/tr>
Males<\/td>27<\/td>21<\/td>21<\/td>6<\/td>4<\/td>16<\/td>18<\/td>7<\/td>10<\/td>17<\/td>25<\/td>2<\/td>10<\/td><\/tr>
Females<\/td>7<\/td>4<\/td>4<\/td>0<\/td>1<\/td>3<\/td>4<\/td>2<\/td>5<\/td>4<\/td>5<\/td>1<\/td>1<\/td><\/tr>
No data<\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td>1<\/td><\/tr>
Proportion positive (%)<\/strong><\/td>4.5%<\/strong><\/td>6.0%<\/strong><\/td>3.6%<\/strong><\/td>1.8%<\/strong><\/td>5.1%<\/strong><\/td>5.3%<\/strong><\/td>5.9%<\/strong><\/td>7.6%<\/strong><\/td>5.8%<\/strong><\/td>17.8%<\/strong><\/td>14.8%<\/strong><\/td>2.0%<\/strong><\/td>6.7%<\/strong><\/td><\/tr>
Males<\/td>4.8%<\/td>6.0%<\/td>3.8%<\/td>2.5%<\/td>5.6%<\/td>6.2%<\/td>6.8%<\/td>8.5%<\/td>5.4%<\/td>18.1%<\/td>17.4%<\/td>2.0%<\/td>7.5%<\/td><\/tr>
Females<\/td>3.6%<\/td>3.2%<\/td>2.7%<\/td>0.0%<\/td>3.7%<\/td>2.9%<\/td>3.7%<\/td>5.6%<\/td>6.8%<\/td>16.7%<\/td>8.5%<\/td>2.0%<\/td>2.4%<\/td><\/tr>
Age <25<\/strong><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>68<\/td>53<\/td>86<\/td>57<\/td>0<\/td>24<\/td>14<\/td>3<\/td>11<\/td>8<\/td>2<\/td>3<\/td>4<\/td><\/tr>
Number of PWID with a positive test result<\/td>2<\/td>0<\/td>1<\/td>0<\/td>0<\/td>0<\/td>1<\/td>0<\/td>1<\/td>1<\/td>0<\/td>0<\/td>4<\/td><\/tr>
Proportion positive (%)<\/td>2.9%<\/td>0.0%<\/td>1.2%<\/td>0.0%<\/td>0.0%<\/td>0.0%<\/td>7.1%<\/td>0.0%<\/td>9.1%<\/td>12.5%<\/td>0.0%<\/td>0.0%<\/td>0.0%<\/td><\/tr>
Age 25-34<\/strong><\/strong><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>434<\/td>225<\/td>340<\/td>137<\/td>20<\/td>90<\/td>34<\/td>15<\/td>44<\/td>15<\/td>16<\/td>18<\/td>13<\/td><\/tr>
Number of PWID with a positive test result<\/td>24<\/td>10<\/td>9<\/td>1<\/td>2<\/td>3<\/td>4<\/td>2<\/td>3<\/td>2<\/td>4<\/td>0<\/td>0<\/td><\/tr>
Proportion positive (%)<\/td>5.5%<\/td>4.4%<\/td>2.6%<\/td>0.7%<\/td>10.0%<\/td>3.3%<\/td>11.8%<\/td>13.3%<\/td>6.8%<\/td>13.3%<\/td>25.0%<\/td>0.0%<\/td>0.0%<\/td><\/tr>
Age > 34<\/strong><\/strong><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>254<\/td>196<\/td>272<\/td>138<\/td>78<\/td>245<\/td>326<\/td>100<\/td>204<\/td>95<\/td>185<\/td>129<\/td>163<\/td><\/tr>
Number of PWID with a positive test result<\/td>8<\/td>15<\/td>15<\/td>5<\/td>3<\/td>16<\/td>17<\/td>7<\/td>11<\/td>18<\/td>26<\/td>3<\/td>12<\/td><\/tr>
Proportion positive (%)<\/td>3.1%<\/td>7.7%<\/td>5.5%<\/td>3.6%<\/td>3.8%<\/td>6.5%<\/td>5.2%<\/td>7.0%<\/td>5.4%<\/td>18.9%<\/td>14.1%<\/td>2.3%<\/td>7.4%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Prevalence of hepatitis C infection among people who inject drugs (PWID) over the period 2013 – 2025<\/strong><\/p>\n\n\n\n

<\/td>2013<\/strong><\/td>2014<\/strong><\/td>2015<\/strong><\/td>2016<\/strong><\/td>2017<\/strong><\/td>2018<\/strong><\/td>2019<\/strong><\/td>2020<\/strong><\/td>2021<\/strong><\/td>2022<\/strong><\/td>2023<\/strong><\/td>2024<\/strong><\/td>2025<\/strong><\/td><\/tr>
Total number of PWID who were tested<\/strong><\/strong><\/td>812<\/strong><\/td>658<\/strong><\/td>698<\/strong><\/td>332<\/strong><\/td>319<\/strong><\/td>368<\/strong><\/td>383<\/strong><\/td>270<\/strong><\/td>302<\/strong><\/td>262<\/strong><\/td>204<\/strong><\/td>150<\/strong><\/td>180<\/strong><\/td><\/tr>
Males<\/td>601<\/td>367<\/td>550<\/td>240<\/td>234<\/td>265<\/td>272<\/td>175<\/td>217<\/td>192<\/td>145<\/td>99<\/td>133<\/td><\/tr>
Females<\/td>211<\/td>123<\/td>148<\/td>92<\/td>85<\/td>103<\/td>111<\/td>95<\/td>85<\/td>70<\/td>59<\/td>49<\/td>42<\/td><\/tr>
No data<\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td>2<\/td>5<\/td><\/tr>
Number of PWID with a positive test result<\/strong><\/td>509<\/strong><\/td>439<\/strong><\/td>430<\/strong><\/td>192<\/strong><\/td>245<\/strong><\/td>241<\/strong><\/td>300<\/strong><\/td>187<\/strong><\/td>241<\/strong><\/td>197<\/strong><\/td>175<\/strong><\/td>107<\/strong><\/td>116<\/strong><\/td><\/tr>
Males<\/td>381<\/td>242<\/td>349<\/td>159<\/td>180<\/td>189<\/td>229<\/td>126<\/td>181<\/td>150<\/td>129<\/td>76<\/td>88<\/td><\/tr>
Females<\/td>128<\/td>78<\/td>81<\/td>33<\/td>65<\/td>52<\/td>71<\/td>61<\/td>60<\/td>47<\/td>46<\/td>30<\/td>23<\/td><\/tr>
No data<\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td>1<\/td>5<\/td><\/tr>
Proportion positive (%)<\/strong><\/td>62.7%<\/strong><\/td>66.7%<\/strong><\/td>61.6%<\/strong><\/td>57.8%<\/strong><\/td>76.8%<\/strong><\/td>65.5%<\/strong><\/td>78.3%<\/strong><\/td>69.3%<\/strong><\/td>79.8%<\/strong><\/td>75.2%<\/strong><\/td>85.8%<\/strong><\/td>71.3%<\/strong><\/td>64.4%<\/strong><\/td><\/tr>
Males<\/td>63.4%<\/td>65.9%<\/td>63.5%<\/td>66.25%<\/td>76.9%<\/td>71.3%<\/td>84.2%<\/td>72.0%<\/td>83.4%<\/td>78.1%<\/td>89.0%<\/td>76.8%<\/td>66.2%<\/td><\/tr>
Females<\/td>60.7%<\/td>63.4%<\/td>54.7%<\/td>35.9%<\/td>76.5%<\/td>50.5%<\/td>64.0%<\/td>64.2%<\/td>70.6%<\/td>67.1%<\/td>78.0%<\/td>61.2%<\/td>54.8%<\/td><\/tr>
Age <25<\/strong><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>76<\/td>50<\/td>86<\/td>57<\/td>12<\/td>24<\/td>14<\/td>6<\/td>11<\/td>16<\/td>2<\/td>3<\/td>4<\/td><\/tr>
Number of PWID with a positive test result<\/td>45<\/td>19<\/td>45<\/td>29<\/td>5<\/td>3<\/td>1<\/td>0<\/td>4<\/td>4<\/td>0<\/td>0<\/td>0<\/td><\/tr>
Proportion positive (%)<\/td>59.2%<\/td>38.0%<\/td>52.3%<\/td>50.9%<\/td>41.7%<\/td>12.5%<\/td>7.2%<\/td>0.0%<\/td>36.4%<\/td>25.0%<\/td>0.0%<\/td>0.0%<\/td>0.0%<\/td><\/tr>
Age 25-34<\/strong><\/strong><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>207<\/td>228<\/td>340<\/td>137<\/td>96<\/td>96<\/td>36<\/td>24<\/td>53<\/td>22<\/td>16<\/td>18<\/td>13<\/td><\/tr>
Number of PWID with a positive test result<\/td>173<\/td>151<\/td>196<\/td>81<\/td>60<\/td>47<\/td>35<\/td>15<\/td>33<\/td>11<\/td>14<\/td>8<\/td>5<\/td><\/tr>
Proportion positive (%)<\/td>83.6%<\/td>66.2<\/td>57.7%<\/td>59.1%<\/td>62.5%<\/td>49.0%<\/td>97.2%<\/td>62.5%<\/td>62.3%<\/td>50.0%<\/td>87.5%<\/td>44.4%<\/td>38.5%<\/td><\/tr>
Age > 34<\/strong><\/strong><\/strong><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>287<\/td>212<\/td>272<\/td>138<\/td>211<\/td>248<\/td>333<\/td>240<\/td>238<\/td>224<\/td>186<\/td>129<\/td>163<\/td><\/tr>
Number of PWID with a positive test result<\/td>207<\/td>150<\/td>189<\/td>82<\/td>180<\/td>191<\/td>264<\/td>172<\/td>204<\/td>182<\/td>161<\/td>99<\/td>111<\/td><\/tr>
Proportion positive (%)<\/td>72.1%<\/td>70.8%<\/td>69.5%<\/td>59.4%<\/td>85.3%<\/td>77.0%<\/td>79.3%<\/td>71.7%<\/td>85.7%<\/td>81.25%<\/td>86.6%<\/td>76.7%<\/td>68.1%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Prevalence of syphilis infection among people who inject drugs (PWID) over the period 2012 – 2025<\/strong><\/p>\n\n\n\n

<\/td>2012<\/strong><\/td>2013<\/strong><\/td>2014<\/strong><\/td>2015<\/strong><\/td>2016<\/strong><\/td>2017<\/strong><\/td>2018<\/strong><\/td>2019<\/strong><\/td>2020<\/strong><\/td>2021<\/strong><\/td>2024<\/strong><\/td>2025<\/strong><\/td><\/tr>
Total number of PWID who were tested<\/strong><\/strong><\/td>637<\/strong><\/td>777<\/strong><\/td>620<\/strong><\/td>698<\/strong><\/td>332<\/strong><\/td>319<\/strong><\/td>361<\/strong><\/td>369<\/strong><\/td>254<\/strong><\/td>301<\/strong><\/td>149<\/strong><\/td>179<\/strong><\/td><\/tr>
Males<\/td>429<\/td>551<\/td>351<\/td>550<\/td>240<\/td>234<\/td>265<\/td>350<\/td>162<\/td>217<\/td>99<\/td>133<\/td><\/tr>
Females<\/td>208<\/td>226<\/td>109<\/td>148<\/td>92<\/td>85<\/td>96<\/td>19<\/td>92<\/td>84<\/td>48<\/td>41<\/td><\/tr>
No data<\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td>2<\/td>5<\/td><\/tr>
Number of PWID with a positive test result<\/strong><\/td>71<\/strong><\/td>46<\/strong><\/td>43<\/strong><\/td>28<\/strong><\/td>17<\/strong><\/td>17<\/strong><\/td>12<\/strong><\/td>26<\/strong><\/td>13<\/strong><\/td>23<\/strong><\/td>10<\/strong><\/td>14<\/strong><\/td><\/tr>
Males<\/td>29<\/td>21<\/td>19<\/td>14<\/td>10<\/td>8<\/td>8<\/td>18<\/td>8<\/td>16<\/td>5<\/td>11<\/td><\/tr>
Females<\/td>42<\/td>25<\/td>11<\/td>14<\/td>7<\/td>9<\/td>4<\/td>8<\/td>5<\/td>7<\/td>5<\/td>3<\/td><\/tr>
Proportion positive (%)<\/strong><\/td>11.1%<\/strong><\/td>5.9%<\/strong><\/td>6.9%<\/strong><\/td>4.0%<\/strong><\/td>5.1%<\/strong><\/td>5.3%<\/strong><\/td>3.3%<\/strong><\/td>7.0%<\/strong><\/td>5.1%<\/strong><\/td>7.6%<\/strong><\/td>6.7%<\/strong><\/td>7.8%<\/strong><\/td><\/tr>
Males<\/td>6.8%<\/td>3.8%<\/td>5.4%<\/td>2.5%<\/td>4.2%<\/td>3.4%<\/td>3.0%<\/td>5.1%<\/td>4.9%<\/td>7.4%<\/td>5.1%<\/td>8.3%<\/td><\/tr>
Females<\/td>20.2%<\/td>11.1%<\/td>10.1%<\/td>9.5%<\/td>7.6%<\/td>10.6%<\/td>4.2%<\/td>42.1%<\/td>5.4%<\/td>8.3%<\/td>10.4%<\/td>7.3%<\/td><\/tr>
Age <25<\/strong><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>67<\/td>68<\/td>55<\/td>86<\/td>57<\/td>12<\/td>25<\/td>0<\/td>7<\/td>11<\/td>3<\/td>3<\/td><\/tr>
Number of PWID with a positive test result<\/td>3<\/td>3<\/td>3<\/td>2<\/td>3<\/td>2<\/td>0<\/td>0<\/td>0<\/td>0<\/td>0<\/td>0<\/td><\/tr>
Proportion positive (%)<\/td>4.5%<\/td>4.4%<\/td>5.5%<\/td>2.3%<\/td>5.3%<\/td>16.7%<\/td>0.0%<\/td>0.0%<\/td>0.0%<\/td>0.0%<\/td>0.0%<\/td>0.0%<\/td><\/tr>
Age 25-34<\/strong><\/strong><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>408<\/td>448<\/td>210<\/td>340<\/td>137<\/td>96<\/td>94<\/td>9<\/td>20<\/td>53<\/td>18<\/td>13<\/td><\/tr>
Number of PWID with a positive test result<\/td>44<\/td>26<\/td>15<\/td>10<\/td>2<\/td>13<\/td>2<\/td>3<\/td>1<\/td>4<\/td>0<\/td>0<\/td><\/tr>
Proportion positive (%)<\/td>10.8%<\/td>5.8%<\/td>7.1%<\/td>2.9%<\/td>1.5%<\/td>13.5%<\/td>2.1%<\/td>33.3%<\/td>5.0%<\/td>7.6%<\/td>0.0%<\/td>0.0%<\/td><\/tr>
Age > 34<\/strong><\/strong><\/strong><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>162<\/td>261<\/td>195<\/td>272<\/td>138<\/td>211<\/td>242<\/td>360<\/td>227<\/td>237<\/td>128<\/td>163<\/td><\/tr>
Number of PWID with a positive test result<\/td>24<\/td>17<\/td>12<\/td>16<\/td>12<\/td>2<\/td>10<\/td>23<\/td>12<\/td>19<\/td>10<\/td>14<\/td><\/tr>
Proportion positive (%)<\/td>14.8%<\/td>6.5%<\/td>6.2%<\/td>5.9%<\/td>8.7%<\/td>0.9%<\/td>4.1%<\/td>6.4%<\/td>5.3%<\/td>8.0<\/td>7.8%<\/td>8.6%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Source: State Psychiatric Hospital for Treatment of Drug Addiction and Alcoholism (SPHTDAA), Sofia, NFP, NCPHA<\/em><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Prevalence of psychoactive substance usePrevalence of medication usePrevalence of drug useDrug Prevention Treatment SupplyTreatment DemandHealth consequencesHarm reduction Drug-related crimesDrug marketDrug use and prisonMonitoring of publicationsAttitudes to legal framework changes Database (1995-2025).xlsx Prevalence of HIV infection among people who inject drugs (PWID) over the period 2013 – 2025 2013 2014 2015 2016 2017 2018 2019 2020 […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[84,87],"tags":[],"_links":{"self":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/5824"}],"collection":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/comments?post=5824"}],"version-history":[{"count":18,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/5824\/revisions"}],"predecessor-version":[{"id":8043,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/5824\/revisions\/8043"}],"wp:attachment":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/media?parent=5824"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/categories?post=5824"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/tags?post=5824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}